Molecular Partners AG-Product Pipeline Review-2015

Molecular Partners AG-Product Pipeline Review-2015

  • Products Id :- GMDHC07196CDB
  • |
  • Pages: 30
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Molecular Partners AG-Product Pipeline Review-2015


Global Markets Direct's, 'Molecular Partners AG-Product Pipeline Review-2015', provides an overview of the Molecular Partners AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Molecular Partners AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Molecular Partners AG including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Molecular Partners AG's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Molecular Partners AG's pipeline products

Reasons To Buy

Evaluate Molecular Partners AG's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Molecular Partners AG in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Molecular Partners AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Molecular Partners AG and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Molecular Partners AG

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Molecular Partners AG and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Molecular Partners AG Snapshot 5

Molecular Partners AG Overview 5

Key Information 5

Key Facts 5

Molecular Partners AG-Research and Development Overview 6

Key Therapeutic Areas 6

Molecular Partners AG-Pipeline Review 8

Pipeline Products by Stage of Development 8

Pipeline Products-Monotherapy 9

Pipeline Products-Out-Licensed Products 10

Out-Licensed Products/Combination Treatment Modalities 11

Molecular Partners AG-Pipeline Products Glance 12

Molecular Partners AG-Clinical Stage Pipeline Products 12

Phase I Products/Combination Treatment Modalities 12

Molecular Partners AG-Early Stage Pipeline Products 13

Preclinical Products/Combination Treatment Modalities 13

Discovery Products/Combination Treatment Modalities 14

Molecular Partners AG-Drug Profiles 15

MP-0250 15

Product Description 15

Mechanism of Action 15

R&D Progress 15

MP-0274 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

Recombinant Protein 1 for Cancer 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

Recombinant Protein 2 for cancer 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

Recombinant Proteins 1 for Ophthalmology 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

Recombinant Proteins 2 for Ophthalmology 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

Recombinant Proteins 3 for Ophthalmology 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

Recombinant Proteins 4 for Opthalmology 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Recombinant Proteins 5 for Ophthalmology 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Molecular Partners AG-Pipeline Analysis 24

Molecular Partners AG-Pipeline Products by Target 24

Molecular Partners AG-Pipeline Products by Route of Administration 25

Molecular Partners AG-Pipeline Products by Molecule Type 26

Molecular Partners AG-Pipeline Products by Mechanism of Action 27

Molecular Partners AG-Locations And Subsidiaries 28

Head Office 28

Appendix 29

Methodology 29

Coverage 29

Secondary Research 29

Primary Research 29

Expert Panel Validation 29

Contact Us 29

Disclaimer 30

List of Tables

Molecular Partners AG, Key Information 5

Molecular Partners AG, Key Facts 5

Molecular Partners AG-Pipeline by Indication, 2015 7

Molecular Partners AG-Pipeline by Stage of Development, 2015 8

Molecular Partners AG-Monotherapy Products in Pipeline, 2015 9

Molecular Partners AG-Out-Licensed Products in Pipeline, 2015 10

Molecular Partners AG-Out-Licensed Products/ Combination Treatment Modalities, 2015 11

Molecular Partners AG-Phase I, 2015 12

Molecular Partners AG-Preclinical, 2015 13

Molecular Partners AG-Discovery, 2015 14

Molecular Partners AG-Pipeline by Target, 2015 24

Molecular Partners AG-Pipeline by Route of Administration, 2015 25

Molecular Partners AG-Pipeline by Molecule Type, 2015 26

Molecular Partners AG-Pipeline Products by Mechanism of Action, 2015 27

List of Figures

Molecular Partners AG-Pipeline by Top 10 Indication, 2015 7

Molecular Partners AG-Pipeline by Stage of Development, 2015 8

Molecular Partners AG-Monotherapy Products in Pipeline, 2015 9

Molecular Partners AG-Out-Licensed Products in Pipeline, 2015 10

Molecular Partners AG-Pipeline by Top 10 Target, 2015 24

Molecular Partners AG-Pipeline by Top 10 Molecule Type, 2015 26

Molecular Partners AG-Pipeline Products by Top 10 Mechanism of Action, 2015 27

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of Molecular Partners AG; Molecular Partners AG - Key Therapeutics; Molecular Partners AG - Pipeline Overview and Promising Molecules; Molecular Partners AG - News; Molecular Partners AG - Latest Updates; Molecular Partners AG - Pipeline; Molecular Partners AG - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 108780
Site License
USD 3000 INR 217560
Corporate User License
USD 4500 INR 326340



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]